# Alaska Medicaid Redesign Quality and Cost Effectiveness Targets Report

September 2019

Submitted to Adam Crum, Commissioner, Alaska Department of Health and Social Services

Prepared by Ashley Christopherson, DHSS Project Lead Alaska Medicaid Redesign Quality and Cost Effectiveness Targets Stakeholder Workgroup




# **GOALS FOR MEDICAID REDESIGN + EXPANSION**











# TABLE OF CONTENTS

Foreword	1
Executive Summary	2
Project Background	
Methodology	
Demonstrating Performance	
Coordination with Redesign efforts	
APPENDIX A – 2017 Performance Measure Results	
APPENDIX B – Quality and Cost Effectiveness Targets Stakeholder Workgroup	10
APPENDIX C – Performance Measure Descriptions and Performance Targets	11
APPENDIX D – Potential Future Measure List	



# **FORWARD**

This report is submitted to Adam Crum, Commissioner, Alaska Department of Health and Social Services, from the Alaska Medicaid Redesign Quality and Cost Effectiveness Targets Stakeholder Workgroup.

## **EXECUTIVE SUMMARY**

In October 2016, the Department of Health and Social Services (Department) convened the Medicaid Redesign Quality and Cost Effectiveness Targets Stakeholder Workgroup (QCE) and tasked the group with identifying Medicaid performance measures the Department could use to evaluate and monitor the overall quality of the Medicaid program during implementation of Medicaid redesign efforts. In 2017, the QCE recommended 18 Medicaid performance measures and corresponding annual and five-year performance targets for the recommended measures. The Department adopted each of the workgroup's recommendations.

During the course of the QCE workgroup's discussions, one measure was removed from the recommended list of measures and placed on the *Potential Future Measures* list. This action was necessary due to the absence of a reliable data source for performance measurement. This reduced the final list of performance measures to 17. In addition, after extensive review by the Department and its consultant Milliman, Inc., results on a second measure were placed on hold until additional assurances were received on the methodology used to calculate performance. For the first year the before mentioned measure, CH.3: Hospital Readmission within 30 days, will now be monitored and reported on. The unique features of this measure will be discussed in this report.

The report also transmits the results of the first and second years of performance measured against the performance baseline for services delivered during state fiscal year 2017. In summary, results of first-year performance demonstrate that the program met or exceeded annual performance targets for ten measures, partially met performance targets for three measures, and failed to meet performance targets for the remaining three measures. Results of the second-year performance baseline for services delivered during state fiscal year 2018, demonstrate that the program met or exceeded annual performance targets for five measures, partially met targets for three measures, are monitoring numbers for one measure and failed to meet targets for the remaining eight measures.

The following report provides an overview of the QCE's third year activities which includes verifying program performance against the approved measures.

## PROJECT BACKGROUND

The Department of Health and Social Services (here by referred to as the Department) has actively pursued Medicaid program redesign opportunities outlined in Alaska Senate Bill 74 (SB74), which passed the Alaska Legislature in 2016. Legislation requires the Department to identify program quality and cost effectiveness measures and develop annual performance targets for those measures to monitor the Medicaid program as redesign activities unfold. In order to meet these requirements, the Department convened an external stakeholder workgroup to identify and recommend measures and performance targets. The 18-member Medicaid Redesign Quality and Cost Effectiveness Targets Stakeholder Workgroup (QCE) included representatives from hospitals, physician groups, federally qualified health centers, enrollee advocates, tribal health organizations and other health professionals. The workgroup met monthly from October 2016 through July 2017 to develop its recommendations.

At the conclusion of its work in 2017, the QCE submitted a list of 18 quality and cost effectiveness measures and corresponding annual and five-year performance targets it believed would help the Department monitor program quality as Medicaid redesign efforts evolve. The workgroup established a 10 percent performance improvement goal that each measure should either meet or exceed by the end of the five-year performance period. Corresponding annual performance targets represent the program performance necessary to achieve the 10 percent improvement goals within the five-year timeframe. Appendix A includes a description of each measure and corresponding performance goals.

The Department accepted each of the workgroup's recommended measures and performance targets. The process the QCE used to identify the recommended measures and develop the performance targets is discussed in detail in the workgroup's *Alaska Medicaid Redesign Quality and Cost Effectiveness Targets Report, September 2017* report. The report also identified varied issues with available Medicaid claims data used to inform the development of the recommended performance targets, and the lack of staff resources necessary to support the performance monitoring required under the legislation.

To inform the workgroup's development of the performance targets in 2017, the Department worked with Milliman Inc. (Milliman), which was under contract with the Department to provide actuarial support for a variety of SB74 projects. Using a subset of Alaska Medicaid claims from state fiscal years 2015 and 2016, Milliman calculated initial results for each measure requiring calculation from Medicaid claims data. The QCE used the initial results from Milliman to benchmark the annual and five-year performance targets, with the understanding that the final performance measure baselines and corresponding targets would be calculated by the Department the following year using a complete Medicaid claims data set. The final steps necessary to operationalize the measures and performance targets were completed by the workgroup in 2018. These steps focused on affirming the Department's process for calculating measure results and affirming the measure baseline calculations. Completion of these items supports public reporting on the measures for the first time in January 2019. First-year results measure program performance during state fiscal year 2017 with second-year results measuring program performance during fiscal year 2018.

The remainder of this report outlines the process the Department used to calculate and verify the algorithms used to develop baseline rates and measure performance, and transmits the results of second- year performance against the baseline rates.

## **METHODOLOGY**

A subset of the original QCE workgroup continued its work in 2018. Participants included 11 external stakeholders representing physicians, federally qualified health centers, hospitals, tribal health organizations, provider organizations, and specialty providers. The workgroup met four times during the year and focused on two primary tasks: affirming the methodology developed by the Department to calculate performance on identified measures and affirming the baseline from which annual performance will be measured. Appendix B identifies the 2018 QCE Workgroup.

Each of the measures recommended by the QCE workgroup fall into one of three categories: 1) the measure (and corresponding algorithm) was developed by either the Centers for Medicare and Medicaid Services (CMS) or the National Committee for Quality Assurance (NCQA), and is a recommended national measure; 2) the measure is based on a nationally recommended measure but both the measure and the algorithm were modified to provide more specific information on Alaska Medicaid performance; or 3) the measure evaluates a unique aspect of the Alaska Medicaid program such as beneficiary satisfaction with care received or per enrollee program costs. Measures that fall into categories 1 and 2 are calculated using Medicaid claims data. A variety of sources are used to identify performance on measures included in category 3, including beneficiary surveys and program financial reports. Appendix C includes details on each measure including the data source used to identify performance.

Milliman provided technical assistance as needed during the process and helped test some of the final algorithms to validate measure results. After working through data discrepancies, Milliman affirmed the reasonableness of the methodology and algorithms developed by the Department and the use of the algorithm methodology to help track progress toward meeting program performance goals aside from the two measures detailed below. A copy of the Milliman Inc., Alaska Medicaid Quality Measures: Documentation of Peer Review is available upon request.

"Based on our review of DHSS methodology and comparison of DHSS results relative to our independent analysis, we believe that DHSS has established a reasonable methodology to both establish the baseline levels for each of the quality measures and track progress towards DHSS goals over time."

Milliman Inc., Alaska Medicaid Quality Measures: Documentation of Peer Review. September 4, 2018.

The Department identified two measures for which there remained broader than expected variation between the Department's baseline calculations and Milliman's initial calculations. These measures included:

- B.3 Initiation Engagement of Alcohol and Other Drug Dependence Treatment
- CH.3 Hospital Readmission within 30 Days of Discharge

#### Measure B.2 - Medical Assistance with Smoking and Tobacco Use

Unfortunately, due to limitations of the Medicaid claims data and the Department's commitment to not require additional provider reporting, the QCE workgroup was unable to find a measure that could reliably and consistently identify the number of Medicaid beneficiaries who either smoked or used a tobacco product. The workgroup met with staff from the Department's Division of Public Health to learn more about population

health surveys and how information gathered through such could potentially be used to help measure Medicaid program performance on smoking and tobacco use cessation. After an extensive discussion on the applicability of population health surveys to specific Medicaid program performance, the QCE workgroup rejected the use of information gathered through a population survey as an effective means to measure activities within the Medicaid program. The workgroup met with additional parties from the State of Alaska and based on potential project ideas, voted to move the proxy measure from the active measure list to the "Potential Future Measures" list (Appendix D). Measure B.2 will remain on the Potential Future Measures list until a reliable data source is identified

#### Measure CH.3 Hospital Readmission within 30 Days of Discharge

Discrepancies with the calculation of measure CH.3 Hospital Readmission within 30 Days of Discharge persisted despite multiple reviews. During the first year of reporting, it was decided that in order to ensure the reliability of the algorithm and calculation methodology for this measure, assistance would be requested from the National Committee for Quality Assurance before performance on this measure is reported and the Department placed this measure on hold.

In September 2019, this measure was again reviewed and preliminary data was entered for fiscal years 2017 and 2018. However, due to persistent anomalies such as the opioid crisis and the Behavioral Health 1115 demonstration waiver, data calculated for this measure will continue to be monitored and results will not be finalized until all issues are identified and resolved.

## DEMONSTRATING PERFORMANCE

As noted above, the QCE workgroup used the initial measure calculations developed by Milliman to inform development of annual performance targets. As the first step to benchmarking performance, the QCE workgroup set a basic goal to improve performance on each measure by 10% within five years. Annual performance targets were then established based on the final five-year performance goals.

In 2018, the QCE workgroup finalized the baseline results for all measures expect measures B.3 and CH.3, as explained above. The baseline results represent Medicaid services delivered in state fiscal year 2016 and serve as the anchor for determining performance improvement over the next five years.

Performance improvement of **10%** is expected for each measure by 2021

The complete list of measures and corresponding final annual and five-year performance goals can be found in Appendix C.

For the first- year of review, the Department calculated the first year of performance against the baseline. Using Medicaid claims from services delivered during state fiscal year 2017, first year results indicate the program met or exceeded annual performance targets for ten measures, partially met performance targets for three measures, and failed to meet performance targets for the remaining three measures. Results of the second-year performance baseline for services delivered during state fiscal year 2018, demonstrate that the program met or exceeded annual performance targets for five measures, partially met targets for three measures, are monitoring numbers for one measure and failed to meet targets for the remaining eight measures.

Table 1 includes results of program performance in 2018. A value of Y or N in the table below notes that the performance target was either met or not met for the cohorts reported under the measure. A value of P

identifies performance was met on at least one of the cohorts reported (Appendix A includes all results by applicable age or category cohort).

Table 1. Results of 2018 Second-Year Performance on QCE Measures

Met 2018 Performance Target Measure A.1 Child and Adolescents' Access to Primary Care A.2 Ability to Get Appointment With Provider As Needed Υ B.1 Follow-up After Hospitalization for Mental Illness B.31 Alcohol and Other Drug Dependence Treatment<sup>1</sup> Υ N CH.1 Emergency Department Utilization CH.2 Diabetic A1C Testing Υ CH.3 Hospital Readmission Within 30 days - All Diagnoses Monitor C.1 Medicaid Spending Per Enrollee Ν C.2 Hospitalization Chronic Obstructive Pulmonary Disease C.3 Hospitalizations Attributed to Diabetic Condition γ C.4 Hospitalizations Attributed Congestive Heart Failure M.1 Live Births Weighing Less Than 2,500 Grams Ν M.2 Follow-up After Delivery M.3 Prenatal Care During First Trimester Ν P.1 Childhood Immunization Status Р P.2 Well-Child Visits for Children 0-6 by Age P.3 Developmental Screening in the First Three Years of Life

As seen above, a number of measures were not met during the 2018 review. There are a variety of factors that could be attributed to this. One of the most outstanding is the opioid crisis in Alaska. Opioid use is a statewide concern impacting every age, race and socioeconomic status in Alaska. In 2010-2017, the opioid overdose death rate increased 77%. Emergency Medical Services (EMS) calls more than doubled from 2012-2017 and the rates of opioid-related inpatient hospitalizations exceeded \$23 million in 2017. This surge in opioid use has a factor in the results in a number of measures including: ability to get an appointment with a provider, follow up after care, emergency department utilization, hospital readmission, and live birth rates. The State of Alaska's Statewide Opioid Action Plan is working to combat this problem.

Another reason for increases in hospitalizations is the growth in population. Alaska saw a 1.9% increase in child population, a .9% decrease in aged population, and a 10.2% increase in adult population, resulting in higher hospitalizations, emergency room visits, and longer wait times.

 $Y = Met\ Performance\ Goal;\ P = Partially\ Met\ Performance\ Goal$ 

<sup>&</sup>lt;sup>1</sup> Measure B.2 Medical Assistance with Smoking and Tobacco Cessation, was moved to the *Potential Future Measures List* by the QCE workgroup in 2018.

<sup>&</sup>lt;sup>2</sup> "Opioid Epidemic in Alaska," State of Alaska, September 25, 2019, http://dhss.alaska.gov/dph/Director/Pages/opioids/home.aspx

## COORDINATION WITH REDESIGN FEFORTS

The Department has engaged in a number of initiatives aimed at improving the effectiveness of the Alaska Medicaid program and the overall health of Medicaid enrollees. The Department's initiative to pursue an 1115 demonstration waiver to realign behavioral health services were also authorized under SB74. Once fully implemented, this initiative should have positive impacts on Medicaid enrollee health.

An Administrative Services Organization (ASO) will be used to support behavioral health reform. It is possible the ASO will have responsibility for processing claims for the delivery of behavioral health services covered under the waiver beginning in state fiscal year 2020. Three of the QCE measures will rely on data from claims that are potentially processed by the ASO contractor (measures B.1, B.3 and CH.3). If the ASO is assigned this responsibility, it will also be necessary to coordinate with this contractor to ensure they too are providing the information necessary for the Department to calculate performance on these measures.

Claims information and supporting documentation will be needed from each potential contractor in order to develop a complete picture of program performance. Performance results for state fiscal years 2017 and 2018 will be calculated solely from the Department's MMIS system. However, beginning with state fiscal year 2019 when the first of the new contractors is introduced, these program contractors will become part of the Department's efforts to track and monitor performance based on the measures developed by the QCE workgroup

# **APPENDIX A**

Category	Measure	Program Cohort	Baseline SFY 2016	Target SFY 2017	Actual 2017	Target SFY 2018	Actual SFY 2018	Target SFY 2019	Target	5-YR Target SFY2021
		Age: 12 to 24 mos	87.00%	88.70%	87.80%	90.50%	87.90%	92.20%	94.00%	95.70%
	A.1: Child and Adolescents'	Age: 25 mos to 6 yrs	77.60%	79.20%	78.70%	80.70%	75.80%	82.30%	83.80%	85.40%
	Access to Primary Care Practitioners	Age: 7 yrs to 11 yrs	82.60%	84.30%	82.50%	85.90%	80.90%	87.60%	89.20%	90.90%
Access	Fractitioners	Age: 12 yrs to 19 yrs	83.70%	85.40%	83.70%	87.10%	82%	88.80%	90.40%	92.10%
	A.2: Ability To Get An	Age: 0-21 yrs	67.20%	68.50%	71.00%	69.90%	70.5%	71.20%	72.60%	73.90%
	Appointment w/Provider as Needed	Age: 21+ yrs	60.60%	61.80%	68.70%	63.00%	66.0%	64.20%	65.40%	66.70%
		Child - Acute	34.30%	35.00%	43.10%	35.70%	41.88%	36.40%	37.10%	37.70%
	B.1: Follow-Up After Hospitalization for Mental	Child - Psych	36.30%	37.00%	39.70%	37.70%	43.70%	38.40%	39.20%	39.90%
Behavioral	Illness	Adult - Acute	40.10%	40.90%	43.40%	41.70%	47.83%	42.50%	43.30%	44.10%
Health*		Adult - Psych	41.60%	42.40%	56.30%	43.20%	57.14%	44.10%	44.90%	45.80%
	B.3: Initiation and Engagement of Alcohol and Other Drug	Initiation	31.10%	31.70%	38.10%	32.30%	40.58%	32.90%	33.60%	34.20%
	Dependence Treatment	Engagement	15.00%	15.30%	18.30%	15.60%	19.97%	15.90%	16.20%	16.50%
	CH.1: Emergency Department Utilization (visits/1,000)	All program participants	637.2	624.5	727.3	611.8	690.2	599.1	586.4	573.5
	CH.2: Comprehensive Diabetes	Age: 18-64 yrs	63.10%	64.40%	68.10%	65.70%	67.30%	66.90%	68.20%	69.40%
Chronic	Care: Hemoglobin A1c (HbA1c) Testing	Age: 65-75 yrs	34.60%	35.30%	38.20%	36.00%	38.60%	36.70%	37.40%	38.10%
Illness	CH.3: Hospital readmission w/in	Age 18+ yrs: Mental illness admits	7.10%		9.20%		8.21%			Monitor
	30 days - all diagnoses	Age 18+ yrs: All other admits	6.30%		7.90%		8.87%			Monitor
	C.1: Medicaid spending per	Age: 0-21yrs	\$5,828	\$5,711	\$6,761	\$5,595	\$6,402	\$5,478	\$5,362	\$5,245
	enrollee	Age: 21+ yrs	\$10,436	\$10,319	\$12,283	\$10,203	\$10,818	\$10,086	\$9,970	\$9,392
	C.2: Number of hospitalizations for Chronic Obstructive Pulmonary Disease	Age: 40-64 yrs	43.8	42.9	35.9	42	27	41.1	40.2	39.4
Cost		Age: 65+ yrs	69.8	68.4	57.9	67	71.2	65.6	64.2	62.8
	C.3: Number of hospitalizations for a diabetic condition	Age: 18-64 yrs	22.1	21.7	20.2	21.3	14.9	20.9	20.5	19.9
		Age: 65+ yrs	21.9	21.5	13.7	21.1	18.7	20.7	20.3	19.7
	C.4: Number of hospitalizations for Congestive Heart Failure	Age: 18-64 yrs	14.4	14.1	15.2	13.8	16.5	13.5	13.2	13
		Age: 65+ yrs	58.9	58	54.8	57.1	69.7	56.2	55.3	53
	M.1: Live Births Weighing Less than 2,500 Grams	All program participants	6.80%	6.70%	6.30%	6.60%	7.30%	6.40%	6.30%	6.10%
Maternal	M.3: Percent of newborns whose mothers had prenatal visit during first trimester	All program participants	77.90%	79.50%	80.60%	81.00%	80.00%	82.60%	84.10%	85.70%
	P.1: Childhood Immunization	Age: 19-35 mos	59.50%	60.70%	62.70%	61.90%	59.16%	63.10%	64.30%	65.50%
		Second yr of life	1.53	1.56	2.04	1.59	1.93	1.62	1.65	1.68
		Third yr of life	0.61	0.62	0.89	0.63	0.81	0.65	0.66	0.67
	P.2: Average Number of Well- Child Visits	Fourth yr of life	0.55	0.56	0.55	0.57	0.5	0.58	0.59	0.61
Preventive		Fifth yr of life	0.6	0.61	0.57	0.62	0.54	0.64	0.65	0.66
		Sixth yr of life	0.16	0.16	0.54	0.17	0.5	0.17	0.17	0.18
		First yr of life	12.90%	13.20%	13.10%	13.40%	14.60%	13.70%	13.90%	14.20%
	P.3: Developmental Screenings	Second yr of life	10.60%	10.80%	9.30%	11.00%	9.85%	11.20%	11.40%	11.70%
	First Three Years of Life	Third yr of life	5.90%	6.00%	6.30%	6.10%	4.99%	6.20%	6.30%	6.50%
2	s denoted in red font indicate perfo	Ages 0-3 combined	10.00%	10.20%	9.80%	10.40%	9.88%	10.60%	10.80%	11.00%

Results denoted in red font indicate performance was not met on the established target Performance calculations completed September 2019

<sup>\*</sup> Measure B.2 Medical Assistance with Smoking and Tobacco Use Cessation has been deferred until a data source is found

# **APPENDIX B**

# ALASKA MEDICAID REDESIGN QUALITY AND COST EFFECTIVENESS TARGETS STAKEHOLDER WORKGROUP

## 2018 WORKGROUP MEMBERS

Samantha Ali	Occupational Therapist, Southcentral Foundation	Anchorage
David Branding	Chief Executive Officer, Juneau Alliance for Mental Health, Inc.	Juneau
Shelley Deering	Regional Manager, Airlift Northwest	Anchorage
Jerry Jenkins	Chief Executive Officer, Anchorage Community Mental Health Services	Anchorage
Keren Kelley	Executive Director, Homer Senior Citizens, Inc	Homer
Jeanette Lacey-Dunn	Director of Case Management, Bartlett Hospital	Juneau
Jacqueline Marcus-Ledford	Director of Performance Improvement, Yukon- Kuskokwim Health Corporation	Bethel
Jeannie Monk	Vice President, Alaska State Hospital and Nursing Home Association	Juneau
Nick Papacostas, MD	U.S. Army, Joint Base Elmendorf-Richardson	Anchorage
Jim Roberts	Liaison, Intergovernmental Affairs, Alaska Native Tribal Health Consortium	Anchorage
Michelle Rothoff, MD	Physician, Anchorage Neighborhood Health Center	Anchorage

## 2018 ALASKA DEPARTMENT OF HEALTH AND SOCIAL SERVICES REPORT STAFF

Donna Steward	Project Leader, DHSS Office of The Commissioner	Anchorage
Heidi Barnes	MAA, DHSS Office of Rate Review	Anchorage

# **APPENDIX C**

# Alaska Medicaid Program Quality and Cost Effectiveness Measure ACCESS I A.1 Children and Adolescents' Access to Primary Care

	ACCE35	A.1 Ciliuren and Add	Diescents Ac	cess to Filliary	Care	
			2016	2017	2018	2021 FIVE
NUMBER	MEASURE	COHORT	BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL
	Child and Age 12-24 mos 87.00% 87.80%	87.90%	95.70%			
۸.1	Adolescents' Access	Age 25 mos-6 yrs	77.60%	78.70%	75.80%	85.40%
A.1	to Primary Care	Age 7-11 yrs	Age 7-11 yrs 82.60% 82.50% 80.90%	90.90%		
	Practitioners	Age 12-19 yrs	83.70%	83.70%	82.00%	92.10%

**Description**: Percentage of children 12 months to 19 years who had a visit with a primary care practitioner during the reporting year.

**Measure Origin**: Centers for Medicare and Medicaid Services (CMS): Core Set of Children's Health Care Quality Measures for Medicaid and CHIP.

Data Source: Medicaid claims data.

Comparable HEDIS Measure: Yes. https://www.ncqa.org/hedis/measures/

**Note:** This measure is annually reported to CMS and in accordance with CMS reporting requirements, calculations are performed using calendar year data rather than state fiscal year data. All other calculated measures use state fiscal year data.

	Alaska Medicaid Program Quality and Cost Effectiveness Measure							
	ACCESS   A.2 A	Ability to Get Appoint	ment With P	rovider As Need	led			
			2016	2017	2018	2021 FIVE		
NUMBER	MEASURE	COHORT	BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL		
A.2	Ability to Get an Appointment for Care	Age 0-21 yrs	67.20%	71.00%	70.5%	73.90%		
A.2	As Needed	Age 21+ yrs	60.60%	68.70%	66.0%	66.70%		

**Description**: Adult's perception of whether they were able to get an appointment as quickly as the adult felt was necessary. Parent's perception of whether they were able to get an appointment for their child as quickly as the parent felt was necessary.

Measure Origin: National Consumer Assessment of Healthcare Providers and Systems (CAHPS) Survey.

**Data Source**: Annual CAHPS Survey. **Comparable HEDIS Measure**: No

#### Alaska Medicaid Program Quality and Cost Effectiveness Measure

#### BEHAVIORAL HEALTH | B.1 Follow-up After Hospitalization for Mental Illness

NUMBER			2016	2017	2018	2021 FIVE
	MEASURE	COHORT	BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL
		Child - Acute	34.30%	43.10%	41.88%	37.70%
D 1	Follow-up After	Child - Psych	36.30%	39.70%	43.71%	39.90%
B.1	Hospitalization for Mental Illness	Adult - Acute	40.10%	43.40%	47.83%	44.10%
		Adult - Psych	41.60%	56.30%	57.14%	45.80%

**Description**: Percent of discharges for children ages 6-20 and adults age 21+ years hospitalized for treatment of a mental health diagnosis who had an outpatient visit, intensive outpatient encounter, or partial hospitalization with a mental health practitioner w/in 30 days of discharge.

**Measure Origin**: CMS: Core Set of Children's Health Care Quality Measures for Medicaid and CHIP; Core Set of Adult Health Care Quality Measures for Medicaid.

Data Source: Medicaid claims data.

Comparable HEDIS Measure: Yes. https://www.ncqa.org/hedis/measures/

Note: Acute refers to services provided in a non-specialty hospital; Psych refers to services provided in a psychiatric hospital

## Alaska Medicaid Program Quality and Cost Effectiveness Measure

### BEHAVIORAL HEALTH | B.32 Alcohol and Other Drug Dependence Treatment

			2016	2017	2018	2021 FIVE
NUMBER	MEASURE	COHORT	BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL
	Initiation and Engagement of	Initiation	31.10%	38.10%	40.58%	34.20%
B.3	Alcohol and Other Drug Dependent Treatment	Engagement	15.00%	18.30%	19.57%	16.50%

Measure Origin: CMS: Core Set of Adult Health Care Quality Measures for Medicaid.

Data Source: Medicaid claims data.

Comparable HEDIS Measure: Yes https://www.ncga.org/hedis/measures/

**Note:** *Initiation* identifies individuals with a new episode of alcohol or other drug dependence who initiated treatment within 14 days of diagnosis. *Engagement* identifies individuals who both initiated treatment and engaged in two or more additional services within 30 days of the initial diagnosis.

#### Alaska Medicaid Program Quality and Cost Effectiveness Measure CHRONIC HEALTH | CH.1 Emergency Department Utilization 2016 2017 2018 **2021 FIVE** COHORT **NUMBER MEASURE** BASELINE PERFORMANCE PERFORM -YEAR GOAL ANCE **Emergency Department** CH.1 Utilization (visits per All program enrollees 637.2 727.3 690.16 573.5 1,000)

**Description**: The number of emergency Department visits per 1,000 Medicaid enrollees.

Measure Origin: Quality and Cost Effectiveness Targets Stakeholder Workgroup.

**Data Source**: Medicaid claims data. **Comparable HEDIS Measure**: No

# Alaska Medicaid Program Quality and Cost Effectiveness Measure CHRONIC HEALTH | CH.2 Diabetic A1C Testing 2016 2017 2018 2018 NUMBER MEASURE COHORT PERFORM - PERFORM - PERFORM - VICENTIAL PERFORM - PERFORM - VICENTIAL PERFORM - PERFORM - VICENTIAL PERFORM - VICEN

NUMBER	MEASURE	COHORT	2016 BASELINE	2017 PERFORM - ANCE	2018 PERFORM - ANCE	2021 FIVE YEAR GOAL
CH.2	Comprehensive Diabetes Care:	Age 18-64 yrs	63.10%	68.10%	67.30%	69.40%
	Hemoglobin A1c (HbA1c) Testing	Age 65-75	34.60%	38.20%	38.60%	38.10%

**Description**: Percentage of Medicaid enrollees ages 18 to 75 with diabetes (type 1 and type 2) who had a hemoglobin A1c (HbA1c) test during the reporting year.

Measure Origin: CMS: Core Set of Adult Health Care Quality Measures for Medicaid.

Data Source: Medicaid claims data.

Comparable HEDIS Measure: Yes. https://www.ncqa.org/hedis/measures/

# Alaska Medicaid Program Quality and Cost Effectiveness Measure CHRONIC HEALTH | CH.3 Hospital Readmission Within 30 days - All Diagnoses

	CHIROTHIC HEALETT	T Citis Hospital Medali	11551011 1111111	130 days All B	авпозез			
			2016	2017	2018	2021 FIVE		
NUMBER	MEASURE	COHORT	BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL  Monitor		
CH.3	Hospital readmission within 30 days - all	Mental illness admits		8.21%	Monitor			
Сп.3	diagnoses	All other admits	6.30%	7.90%	8.87%	YEAR GOAL		

Measure Origin: CMS: Core Set of Adult Health Care Quality Measures for Medicaid.

Data Source: Medicaid claims data.

Comparable HEDIS Measure: Yes. https://www.ncqa.org/hedis/measures/

**Note:** Due to persistent anomalies in results calculated for this measure, data is being monitored. Performance calculations

will not be finalized until all issues are identified and resolved.

#### Alaska Medicaid Program Quality and Cost Effectiveness Measure **COST | C.1 Medicaid Spending Per Enrollee** 2016 2017 2018 **2021 FIVE NUMBER MEASURE** COHORT **PERFORM -**BASELINE **PERFORMANCE** YEAR GOAL ANCE Age 0-21 yrs \$5,828 \$6,761 \$6,402 \$5,245 Medicaid spending C.1 per enrollee \$12,283 Age 21+ yrs \$10,436 \$10,818 \$9,392

**Description**: Consistent with information currently provided, the Department will produce per member and aggregate costs for non-waiver services by service category. Aggregate annual spending per enrollee will be used to measure performance.

**Measure Origin**: Quality and Cost Effectiveness Targets Stakeholder Workgroup. **Data Source**: DHSS Annual Report: MMIS Medicaid Claim Activity, January 24, 2018

Comparable HEDIS Measure: No

# Alaska Medicaid Program Quality and Cost Effectiveness Measure COST | C.2 Number of Hospitalizations for Chronic Obstructive Pulmonary Disease (COPD)

NUMBER	MEASURE	сонокт	2016	2017	2018	2021 FIVE  - YEAR GOAL  39.4  62.8
	WEASURE	COHORI	BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL
C.2	Number of hospitalizations for	Age 40-64 yrs.	43.8	35.9	27	39.4
	Chronic Obstructive Pulmonary Disease	Age 65+ yrs.	69.8	57.9	71.2	62.8

Description: Per 100,000 enrollee months, number of hospitalizations due to COPD during the reporting period

Measure Origin: CMS: Core Set of Adult Health Care Quality Measures for Medicaid.

**Data Source**: Medicaid claims data. **Comparable HEDIS Measure**: No

Note: Hospitalizations attributed to COPD as a first, second or third diagnoses are included in the measure.

## Alaska Medicaid Program Quality and Cost Effectiveness Measure

#### COST | C.3 Number of Hospitalizations Attributed to a Diabetic Condition

		<u>'</u>					
				2016	2017	2018	2021 FIVE
	NUMBER	MEASURE	COHORT	BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL
	C.3	Number of hospitalizations	Age 18-64 yrs.	22.1	20.2	14.9	19.9
C.3	attributed to a diabetic condition	Age 65+ yrs.	21.9	13.7	18.7	19.7	

**Description**: Per 100,000 enrollee months, number of hospitalizations due to a diabetic condition during reporting period.

Measure Origin: Quality and Cost Effectiveness Targets Stakeholder Workgroup.

**Data Source**: Medicaid claims data. **Comparable HEDIS Measure**: No

Note: Hospitalizations attributed to diabetes as a first, second or third diagnoses are included in the measure.

## Alaska Medicaid Program Quality and Cost Effectiveness Measure

#### **COST | C.4 Number of Hospitalizations Attributed to Congestive Heart Failure**

	•	•				
NUMBER	MEASURE	сонокт	2016	2017	2018	2021 FIVE
			BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL
C.4	Number of hospitalizations due	Age 18-64 yrs.	14.4	15.2	16.5	13
	to Congestive Heart Failure	Age 65+ yrs.	58.9	54.8	69.7	53

**Description**: Per 100,000 enrollee months, number of hospitalizations due to Congestive Heart Failure during reporting period.

Measure Origin: Modified CMS: Core Set of Adult Health Care Quality Measures for Medicaid.

**Data Source**: Medicaid claims data. **Comparable HEDIS Measure**: No

Note: Hospitalizations attributed to congestive heart failure as a first, second or third diagnoses are included in the

measure.

# Alaska Medicaid Program Quality and Cost Effectiveness Measure

### MATERNAL HEALTH | M.1 Live Births Weighing Less Than 2,500 Grams

NUMBER	MEASURE	COHORT	2016	2017	2018	2021 FIVE
			BASELINE	PERFORMANCE	PERFORMANCE	YEAR GOAL
M.1	Live Births Weighing Less Than 2,500 Grams	All live births within program	6.80%	6.70%	7.30%	6.10%

**Description**: Percentage of live births weighing less than 2,500 grams delivered to Medicaid recipients in the state during the reporting period.

Measure Origin: CMS: Core Set of Children's Health Care Quality Measures for Medicaid/CHIP Data Source: Alaska's Indicator-Based Information System for Public Health Data (IBIS).

Comparable HEDIS Measure: Yes. https://www.ncqa.org/hedis/measures/

#### Alaska Medicaid Program Quality and Cost Effectiveness Measure MATERNAL HEALTH | M.2 Postpartum Care 2016 2017 2018 **2021 FIVE NUMBER MEASURE COHORT** YEAR **BASELINE PERFORMANCE PERFORMANCE GOAL** All live births Follow-up after 38.80% M.2 within 40.50% 38.18% 42.70% delivery program

**Description**: Percentage of women who had live births during the reporting year that also had a postpartum visit on or

between 21 and 56 days after delivery.

Measure Origin: CMS: Core Set of Adult Health Care Quality Measures for Medicaid.

Data Source: Medicaid claims data.

Comparable HEDIS Measure: Yes. https://www.ncqa.org/hedis/measures/

**Note**: Calculated results may be lower than actuals due to differences in the codes providers use to identify these services.

Alaska Medicaid Program Quality and Cost Effectiveness Measure  MATERNAL HEALTH   M.3 Prenatal Care During First Trimester							
NUMBER	MEASURE CO	COHORT	2016	2017	2018	2021 FIVE	
			BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL	
M.3	Prenatal Care During First Trimester	All live births within program	77.90%	80.60%	80.08%	85.70%	

**Description**: Percentage of newborns whose mothers had a prenatal visit during first trimester. **Measure Origin**: CMS: Core Set of Children's Health Care Quality Measures for Medicaid/CHIP

Data Source: Medicaid claims data.

Comparable HEDIS Measure: Yes. https://www.ncqa.org/hedis/measures/

**Note**: Calculated results may be lower than actuals due to differences in the codes providers use to identify these services.

Alaska Medicaid Program Quality and Cost Effectiveness Measure								
PREVENTIVE HEALTH   P.1 Childhood Immunization Status								
NUMBER	MEASURE	COHORT	2016	2017	2018	2021 FIVE		
			BASELINE	PERFORMANCE	PERFORM - ANCE	YEAR GOAL		
P.1	Childhood Immunization Status	Age 0-24 mos.	59.50%	62.70%	59.16%	65.50%		

**Description**: Percentage of children in the Alaska Medicaid program age 0-24 months receiving recommended immunizations for age.

Measure Origin: Quality and Cost Effectiveness Targets Stakeholder Workgroup.

Data Source: VacTrAK Immunization Registry of Alaska.

Comparable HEDIS Measure: No

# Alaska Medicaid Program Quality and Cost Effectiveness Measure PREVENTIVE HEALTH | P.2 Well-Child Visits for Children 0-6 by Age

NUMBER	MEASURE	COHORT	2016	2017	2018	2021 FIVE
			BASELINE	PERFORM - ANCE	PERFORM - ANCE	YEAR GOAL
	Average Number of Well Child Visits by Age	Second yr. of life	1.53	2.04	1.93	1.68
		Third yr. of life	0.61	0.89	0.81	0.67
D 2		Fourth yr. of life	0.55	0.55	0.5	0.61
P.2		Fifth yr. of life	0.6	0.57	0.54	0.66
		Sixth yr. of life	0.16	0.54	0.5	0.18

Description: Average number of well child visits during the reporting period, reported by age for children ages 0 to 6.

Measure Origin: Modified CMS: Core Set of Child Health Care Quality Measures for Medicaid.

**Data Source**: Medicaid claims data. **Comparable HEDIS Measure**: No

**Notes**: The workgroup acknowledges that children may be seen more frequently by a provider but that the Medicaid claim submitted by the provider could reflect a purpose separate from a well-child visit. The workgroup's recommendation is to specifically monitor those visits focused on wellness of the child as a means to evaluate opportunities for early detection of adverse health conditions.

## Alaska Medicaid Program Quality and Cost Effectiveness Measure

#### PREVENTIVE HEALTH | P.3 Developmental Screening in the First Three Years of Life

NUMBER	MEASURE	COHORT	2016	2017 PERFORM -	2018 PERFORM -	2021 FIVE
			BASELINE	ANCE	ANCE	YEAR GOAL
P.3	Developmental Screening in First Three Years of Life	First yr. of life	12.90%	13.10%	14.60%	14.20%
		Second yr. of life	10.60%	9.30%	9.85%	11.70%
		Third yr. of life	5.90%	6.30%	4.99%	6.50%
		Ages 0-3 combined	10.00%	9.80%	9.88%	11.00%

**Description**: Percentage of children screened for risk of developmental, behavioral, and social delays using a standardized screening tool in the 12 months preceding their first, second, or third birthday.

Measure Origin: Modified CMS: Core Set of Children's Health Care Quality Measures for Medicaid and CHIP.

**Data Source**: Medicaid claims data. **Comparable HEDIS Measure**: No

**Notes**: The workgroup's desire is to assess the frequency of any developmental screen performed on the child and acknowledges that CMS Core reporting will report on the subset of CMS identified screens as a more narrow focus that reflects national interests.

# **APPENDIX D**

## POTENTIAL FUTURE MEASURES RECOMMENDED BY MEDICAID REDESIGN QUALITY AND COST EFFECTIVENESS TARGETS STAKEHOLDER WORKGROUP

The Medicaid Redesign Quality and Cost Effectiveness Targets Stakeholder Workgroup requests that the Department of Health and Social Services adopt the following Medicaid program performance measures as soon as possible following elimination of program impediments:

#### AFTER PASSAGE OF PREVENTIVE SERVICES REGULATIONS

- Child /Adolescent Major Depressive Disorder: Suicide Risk Assessment
- Chlamydia Screening in Women
- HIV Screening All Ages
- Breast Cancer Screening (BCS)
- Cervical Cancer Screening (CCS)
- Mammogram Screening
- Colorectal Cancer Screening
- LDL-C Screening
- Flu Vaccinations for Adults Age 18 and Older (FVA)
- Flu Vaccinations for Children Age 18 and Under
- HPV Vaccinations for Children Age 18 and Under
- Pneumonia Vaccine for Older Adults
- Alcohol Screening in Pregnant Women
- HIV Screening Pregnant Women
- Diabetes Care Eye Exam
- Diabetes Care LDL Assessment
- Diabetes Care Screening for Nephropathy
- Hypertension Screening for Nephropathy
- Nephropathy Screening for Nephropathy
- Heart Failure Screening for Nephropathy

#### AFTER CONSISTENT DATA SOURCE IS IDENTIFIED

- Child /Adolescent Major Depressive Disorder: Suicide Risk Assessment
- Screening for Clinical Depression and Follow-Up Plan (CDF)
- Body Mass Index Assessment (ABA) for Adults
- Body Mass Index Assessment (ABA) for Children/Adolescents
- Behavioral Health Risk Assessment for Pregnant Women (BHRA)
- Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
- Controlling High Blood Pressure
- Percent of Adult Medicaid Recipients that Smoke
- Medication Management for People with Asthma
- Annual cost of Medicaid per member vs annual cost of Private/Exchange premium
- Adherence to HIV Viral Load Suppression Therapy
- B.2 Medical Assistance with Tobacco Use and Cessation Assistance